BerGenBio, a biotechnology company that employs just 38 people based in Bergen, Norway, and Oxford, England, has developed a drug called bemcentinib, which is currently in phase two of clinical trials. Richard Godfrey, the CEO of BerGenBio, told ABC News that he has high hopes that the drug, which was initially developed to treat cancer, will benefit coronavirus patients. abcNews
Thursday, May 21, 2020
In race to find a COVID-19 treatment, CEO of tiny biotech company is 'very optimistic'
BerGenBio, a biotechnology company that employs just 38 people based in Bergen, Norway, and Oxford, England, has developed a drug called bemcentinib, which is currently in phase two of clinical trials. Richard Godfrey, the CEO of BerGenBio, told ABC News that he has high hopes that the drug, which was initially developed to treat cancer, will benefit coronavirus patients. abcNews
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment